Brain region-specific action of ketamine as a rapid antidepressant.
Min ChenShuangshuang MaHanxiao LiuYiyan DongJingxiang TangZheyi NiYi TanChenchi DuanHui LiHe-Feng HuangYu-Long LiXiaohua CaoChristopher J LingleYan YangHai-Lan HuPublished in: Science (New York, N.Y.) (2024)
Ketamine has been found to have rapid and potent antidepressant activity. However, despite the ubiquitous brain expression of its molecular target, the N -methyl-d-aspartate receptor (NMDAR), it was not clear whether there is a selective, primary site for ketamine's antidepressant action. We found that ketamine injection in depressive-like mice specifically blocks NMDARs in lateral habenular (LHb) neurons, but not in hippocampal pyramidal neurons. This regional specificity depended on the use-dependent nature of ketamine as a channel blocker, local neural activity, and the extrasynaptic reservoir pool size of NMDARs. Activating hippocampal or inactivating LHb neurons swapped their ketamine sensitivity. Conditional knockout of NMDARs in the LHb occluded ketamine's antidepressant effects and blocked the systemic ketamine-induced elevation of serotonin and brain-derived neurotrophic factor in the hippocampus. This distinction of the primary versus secondary brain target(s) of ketamine should help with the design of more precise and efficient antidepressant treatments.
Keyphrases
- pain management
- major depressive disorder
- cerebral ischemia
- spinal cord
- white matter
- resting state
- signaling pathway
- poor prognosis
- type diabetes
- chronic pain
- minimally invasive
- insulin resistance
- functional connectivity
- cognitive impairment
- long non coding rna
- adipose tissue
- subarachnoid hemorrhage
- endothelial cells
- angiotensin ii
- diabetic rats